More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
While the studies on these systems have proven them to be effective in diagnosing and treating COVID in specific cohorts, the varying settings in which they were used can make it difficult to derive definitive conclusions on their efficacy.
A new study utilizing multi-organ MRI scans recently identified organ impairment in 62% of COVID long haulers six months after their initial diagnosis; 29% of these individuals continued to display damage in at least one organ at the 12-month mark.
Quantifiable features of medical images such as pixel intensity, arrangement, color and texture—in a word, radiomics—can help radiologists improve diagnostic accuracy.
Patients who are vaccinated at the time of their COVID-19 diagnosis appear to face a lower risk of new-onset type 2 diabetes than patients who are not vaccinated.
According to new research published in the American Journal of Cardiology, complex CAD appears to affect long-term TAVR outcomes much more for women than it does for men.
Scans on these patients show a combination of fibrosis, thickening, honeycombing, cystic changes and dilation of the bronchi, among other imaging features.
Leading stroke specialists from all over the world gathered in Dallas for the 2023 International Stroke Conference. Catch up on some of the biggest stories that came out of the three-day event.
